Data Sheet 1_Integrating overall survival and health-related quality of life to prioritize first-line systemic therapies for unresectable advanced gastric cancer: a network meta-analysis.docx

The surface under the cumulative ranking curve (SUCRA) was applied to rank all included treatments based on HR-QoL indicators. We further performed an exploratory composite analysis integrating overall-survival and HR-QoL outcomes via the minimum distance criterion.</p>Results<p>In total, 10 RCTs enrolling over 8000 patients and covering six HR-QoL domains met the inclusion criteria. SUCRA analyses indicated that trastuzumab and tislelizumab had the lowest probability of the deterioration of global health status, physical function, nausea/vomiting, appetite loss and pain.

When HR-QoL was combined with overall survival (OS) via an exploratory minimum distance criterion composite analysis, trastuzumab and tislelizumab showed favorable comprehensive performance across most evaluated domains. This composite metric remains exploratory without established uncertainty estimates and should not serve as primary evidence for clinical decision-making.</p>Conclusions<p>This network meta-analysis suggests that trastuzumab (for HER2-positive disease) and tislelizumab (for largely biomarker-unselected populations) deliver the balance between HR-QoL preservation and OS benefit within their respective biomarker-eligible patient subgroups among systemic treatment options for unresectable advanced GC.</p>Systematic Review Registration<p>crd.york.ac.uk/prospero/, identifier CRD420261422326.</p>